Pfizer And Ionis’s Antisense Cholesterol Candidate Sparks Safety Worries
Concerns Despite Phase IIb Win
Executive Summary
Increases in liver enzymes and fat could dampen approval prospects despite vupanorsen meeting its mid-stage primary endpoint, some analysts have said.